KYBORA is pleased to announce that it has successfully helped its client STADA Arzneimittel AG license Xlucane – a Ranibizumab (Lucentis) biosimilar to Bausch Health. This latest transaction reinforces KYBORA’s capability in delivering complex cross border transactions working with leading global pharmaceutical companies. “We are seeing an increase in the number of biosimilar deals around […]

Read more